EXPLORE-OSA Drug Candidate Trial Fully Enrolled
Mineralys Therapeutics’ lorundrostat targets nocturnal hypertension linked to sleep apnea.
Mineralys Therapeutics’ lorundrostat targets nocturnal hypertension linked to sleep apnea.
Researchers suggest higher adherence to the CPAP alternative likely contributed to its benefits for people with obstructive sleep apnea and hypertension.
A recent study highlights the importance of treating pulmonary hypertension in patients with obstructive sleep apnea.
Read MoreMore than 3% of adults worldwide have unruptured blood vessel malformations in the brain called intracranial aneurysms, the majority of which will never rupture.
Read MoreA five-year, $3.4 million grant builds on research that showed a respiratory workout entailing 30 breaths a day can lower blood pressure.
Read MoreAt Baptist Health South Florida, if sleep health is a factor contributing to resistant hypertension, the patient may be referred to the Institute’s Sleep Medicine and Continuous Improvement program.
Read MoreA literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read MoreNew research finds that testing for an inflammatory marker is a stronger predictor than apnea-hypopnea index alone.
Read MoreObstructive sleep apnea is highly prevalent and more severe disease appears to be associated with higher blood pressure among patients with resistant hypertension, a recent study suggests. “We believe that OSA plays an...
Read MoreWork stress and impaired sleep are linked to a threefold higher risk of cardiovascular death in...
Read MoreMidday naps are associated with reduced blood pressure levels and prescription of fewer...
Read More